Tag: GLP-1-agonists
Semaglutide’s lean mass loss exceeds dietary norms — but resistance training may offset the effect
Semaglutide causes lean mass loss exceeding the 25% baseline seen with diet-only weight reduction, but emerging case evidence suggests resistance…
Popular obesity drugs deliver weight loss but fail to improve quality of life or heart health, meta-analysis reveals
A meta-analysis published in The BMJ found that popular obesity drugs such as semaglutide and tirzepatide produce substantial weight loss…
New Oral Weight-Loss Pill Outperforms Semaglutide in Major Clinical Trial
A new once-daily oral medication called orforglipron has outperformed oral semaglutide in a major clinical trial, offering superior weight loss…
Semaglutide Approved for Advanced Liver Disease: First GLP-1 Drug to Treat MASH with Fibrosis
Semaglutide (Wegovy) has become the first glucagon-like peptide-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver…
Eli Lilly’s Obesity Drug Access: What We Know About FDA Approval Pathways
Regulatory pathways and corporate strategy shape early access to obesity drug candidates. Pharmaceutical acquisitions in the metabolic disease sector reflect…